Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results

Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year – showed promise for the triple…

Read More

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma or non-small cell lung cancer with pleural disease undergoing surgery. Light dosimetry measures the amount of laser light given during photodynamic therapy. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to light. The activated drug may kill tumor cells. Using light dosimetry for intraoperative photodynamic therapy may help doctors estimate how much light is delivered during photodynamic therapy and decide if the treatment should be stopped or continued.

Read More

Mesothelioma Awareness Day is September 26, 2018

Mesothelioma Awareness Day will once again take place on September 26, marking 15 consecutive years of awareness aimed to educate and inform society about the deadly cancer caused by exposure to asbestos. Established in 2004 by the Meso Foundation, the event eventually received recognition by the House and U.S. Senate making it a national event…

Read More

Asbestos Related Deaths Reportedly Double Previous Estimations In the United States

Since the dangers of asbestos exposure began to come to light over 40 years ago, regulations have been implemented to ban asbestos in most household products and to severely limit asbestos exposure in the workplace. Asbestos is a known carcinogen that causes lung cancer, asbestosis, mesothelioma, and other life-threatening diseases, and these regulations not only…

Read More

Sarcopenia in Relation to Overall Survival in Peritoneal Mesothelioma

Peritoneal mesothelioma only affects about 500 people each year, but its aggressive nature makes it hard to treat successfully and many who are diagnosed will on average survive only 6 to 12 months. Peritoneal mesothelioma is a cancer affecting the abdominal lining, or peritoneum, which is why it is sometimes referred to as abdominal mesothelioma. Asbestos…

Read More

CAR T-Cell Therapy Research for Mesothelioma and Other Cancers

In malignant pleural mesothelioma, mesothelin – a protein that can be over expressed in many cancers – is present in 80 percent to 90 percent of all these cases. However, it is not common to see mesothelin on mesothelial cells, which allows for potential targeted treatment. CAR T -cell therapy is a type of treatment…

Read More